secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001200375-24-000020
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q2 revenues fall 62% YoY to $8.0M; net loss widens; reiterates FY2024 guidance
--------------------------------------------------------------------------------

- Q2 total revenue $8.0M vs $21.3M YoY; product rev $6.3M vs $11.0M; R&D rev $1.7M vs $10.3M.
- Net loss $22.8M ($0.32/sh) vs $11.5M ($0.17/sh); product gross margin 45% vs 71%.
- Cash $73.2M; expects to fund operations through positive cash flow around end-2026.
- FY2024 guidance reiterated: product rev $38-42M (ex-PAXLOVID), R&D rev $18-22M, product GM 58-63%.
- Received low-to-mid single-digit million-dollar dsRNA ligase order; expects first ECO Synthesis collaboration by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037524000020/0001200375-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037524000020/cdxs-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001200375-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer